CEUDEX: a data base oriented to context-dependent units training in Spanish for continuous speech recognition

C. D. L. Torre,L. A. H. Gómez,D. Merino

DOI: https://doi.org/10.21437/Eurospeech.1995-193

Abstract:

What problem does this paper attempt to address?

Disruption of mitochondrial redox homeostasis as a mechanism of antimony-induced reactive oxygen species and cytotoxicity

Liling Su,Wenpan Fang,Xinyuan Zhao,Longtao Zhu,Lan Gao,Guangdi Chen

DOI: https://doi.org/10.1016/j.ecoenv.2022.113519

IF: 7.129

2022-01-01

Ecotoxicology and Environmental Safety

Abstract:Occupational and environmental Sb exposure has been associated with increased risk of respiratory diseases and lung cancer, but the toxicities and molecular mechanisms of Sb have been less investigated. In the present study, we first analyzed the Sb toxicity profile of lung adenocarcinoma A549 cells, and found that Sb dose-dependently decreased the cell viability and arrested cell cycle at G2/M but did not induce apoptosis. We next investigated the role of reactive oxygen species (ROS) involved in Sb-induced cytotoxicity. The results showed that Sb did not significantly induce cytosolic ROS production by NADPH oxidase (NOX) and the NOX inhibitors did not ameliorate the Sb-induced cell viability loss in A549 cells. However, the level of mitochondrial ROS (mtROS) was significantly increased in Sb-exposed cells and the mitochondria-targeted antioxidant significantly improved cell viability. These results suggested that mitochondria but not NOX is the major source of ROS production and mtROS plays a critical role in Sb-induced cytotoxicity. Furthermore, we found that Sb induced mitochondria dysfunction including the significant decrease of ATP level and mitochondrial membrane potential. Finally, Sb exposure decreased the activity of complex I and complex III, the level of -SH and GSH in mitochondria, and the activity of mitochondrial GR, GPx and TrxR, but increased the mitochondrial SOD activity, suggesting the disruption of mitochondrial redox homeostasis. Taken together, these findings suggested that Sb impaired mitochondrial redox homeostasis, resulting in formation of mtROS, thereby inhibited mitochondrial function and led to cytotoxicity.
Monomethylarsenic Diglutathione Transport By The Human Multidrug Resistance Protein 1 (Mrp1/Abcc1)

Michael W. Carew,Hua Naranmandura,Caley B. Shukalek,X. Chris Le,Elaine M. Leslie

DOI: https://doi.org/10.1124/dmd.111.041673

2011-01-01

Abstract:The ATP-binding cassette (ABC) transporter protein multidrug resistance protein 1 (MRP1; ABCC1) plays an important role in the cellular efflux of the high-priority environmental carcinogen arsenic as a triglutathione conjugate [As(GS)(3)]. Most mammalian cells can methylate arsenic to monomethylarsonous acid (MMA(III)), monomethylarsonic acid (MMA(V)), dimethylarsinous acid (DMA(III)), and dimethylarsinic acid (DMA(V)). The trivalent forms MMA(III) and DMA(III) are more reactive and toxic than their inorganic precursors, arsenite (As(III)) and arsenate (As(V)). The ability of MRP1 to transport methylated arsenicals is unknown and was the focus of the current study. HeLa cells expressing MRP1 (HeLa-MRP1) were found to confer a 2.6-fold higher level of resistance to MMA(III) than empty vector control (HeLa-vector) cells, and this resistance was dependent on GSH. In contrast, MRP1 did not confer resistance to DMA(III), MMA(V), or DMA(V). HeLa-MRP1 cells accumulated 4.5-fold less MMA(III) than HeLa-vector cells. Experiments using MRP1-enriched membrane vesicles showed that transport of MMA(III) was GSH-dependent but not supported by the nonreducing GSH analog, ophthalmic acid, suggesting that MMA(III)(GS)(2) was the transported form. MMA(III)(GS)(2) was a high-affinity, high-capacity substrate for MRP1 with apparent K(m) and V(max) values of 11 mu M and 11 nmol mg(-1)min(-1), respectively. MMA(III)(GS)(2) transport was osmotically sensitive and inhibited by several MRP1 substrates, including 17 beta-estradiol 17-(beta-D-glucuronide) (E(2)17 beta G). MMA(III)(GS)(2) competitively inhibited the transport of E(2)17 beta G with a K(i) value of 16 mu M, indicating that these two substrates have overlapping binding sites. These results suggest that MRP1 is an important cellular protective pathway for the highly toxic MMA(III) and have implications for environmental and clinical exposure to arsenic.
Differential Specificity of the Human and Mouse Multidrug Resistance Protein 4 (MRP4) Orthologs for Arsenic Metabolites

Brayden D. Whitlock,Diane P. Swanlund,X. Chris Le,John D. Schuetz,Susan P. C. Cole,Elaine M. Leslie

DOI: https://doi.org/10.1096/fasebj.30.1_supplement.lb497

2016-04-01

The FASEB Journal

Abstract:An estimated 160 million people world‐wide are exposed to levels of arsenic in their drinking water higher than the limit of 10 ppb (10 μg/L) set by the World Health Organization. Arsenic is a Group 1 (proven) human carcinogen which causes skin, lung, and bladder tumors, and is associated with numerous other adverse health effects, including neuropathy and cardiovascular dysfunctions. Multidrug resistance proteins (MRPs/ABCCs) mediate the cellular efflux of a chemically diverse array of endogenous and xenobiotic metabolites. Substrates include glutathione (GSH) conjugates of inorganic and methylated arsenic species and dimethylarsinic acid (DMA V ). Unlike in humans, arsenic is a poor carcinogen in rodents, requiring at least 100‐fold higher doses for tumour induction. Differences in toxicokinetics between humans and other species are also well documented. We have shown that human MRP4 (hMRP4) reduces the cytotoxicity and cellular accumulation of inorganic and methylated arsenic species, and hMRP4‐enriched membrane vesicle transport studies identified the GSH conjugate of the highly toxic methylated arsenic metabolite monomethylarsonous acid (MMA III ), MMA(GS) 2 , and the major human urinary metabolite DMA V as the transported forms. The objective of the current study was to determine if mouse Mrp4 (mMrp4) conferred resistance to and/or transported the same arsenic species as hMRP4. HEK293 clonal cell lines stably expressing mMrp4 were established and used in cytotoxicity assays. Our results showed that mMrp4 did not confer resistance to any of the arsenic species tested [arsenite (As III ), arsenate (As V ), MMA III , monomethylarsonic acid (MMA V ), dimethylarsinous acid (DMA III ) or DMA V ]. Studies with mMrp4‐enriched membrane vesicles showed that unlike hMRP4, mMrp4 did not transport MMA(GS) 2 or DMA V . Thus, under the conditions tested, arsenicals are not substrates for mMrp4. These results suggest that hMRP4/mMrp4 could contribute to differences in arsenic toxicokinetics between humans and mice. Furthermore, Mrp4/Abcc4(−/−) mice are unlikely to be a relevant model for understanding the in vivo contribution of hMRP4 to arsenic detoxification and elimination. Support or Funding Information Canadian Institutes of Health Research, Alberta Innovates Health Solutions, Faculty of Medicine and Dentistry, University of Alberta

cell biology,biochemistry & molecular biology,biology
Multidrug Resistance Protein 1 ( ABCC1 ) Confers Resistance to Arsenic Compounds in Human Myeloid Leukemic HL-60 Cells

Shi Xu,Yan Fang Zhang,Micheal W. Carew,Wen Hui Hao,Jacky Fong Chuen Loo,Hua Naranmandura,X. Chris Le

DOI: https://doi.org/10.1007/s00204-012-0956-6

2012-01-01

Archives of Toxicology

Abstract:Arsenic trioxide (As(2)O(3)) is established as one of the most effective drugs for treatment of patients with acute promyelocytic leukemia, as well as other types of malignant tumors. However, HL-60 cells are resistant to As(2)O(3), and little is known about the underlying resistance mechanism for As(2)O(3) and its biomethylation products, namely, monomethylarsonous acid (MMA(III)) on the treatment of tumors. In the present study, we investigated the molecular mechanisms underlying iAs(III) and its intermediate metabolite MMA(III)-induced anticancer effects in the HL-60 cells. Here, we show that the HL-60 cells exhibit resistance to inorganic iAs(III) (IC(50) = 10 μM), but are relatively sensitive to its intermediate MMA(III) (IC(50) = 3.5 μM). Moreover, we found that the multidrug resistance protein 1 (MRP1), but not MRP2, is expressed in HL-60 cells, which reduced the intracellular arsenic accumulation, and conferred resistance to inorganic iAs(III) and MMA(III). Pretreatment of HL-60 with MK571, an inhibitor of MRP1, significantly increased iAs(III) and MMA(III)-induced cytotoxicity and arsenic accumulations, suggesting that the expression of MRP1/4 may lead to HL-60 cells resistance to trivalent arsenic compounds.
Precursors of Engine Failures Revealed by Wavelet Analysis

I. Dremin

DOI: https://doi.org/10.1142/9789812796769_0070

2003-04-01

Abstract:
SP1 Mediates MRP1 Upregulation and Multi-Drug Resistance in Human Lung Cancer Cells

Shuli Shao,Yunjianan Feng,Yue Xiao,Yan Li,Weiwei Zhang,Yingning Sun,Bin Zhao,Huaiyong Li,Changhe Wang

DOI: https://doi.org/10.2139/ssrn.3427292

2019-01-01

SSRN Electronic Journal

Abstract:Background: Chemotherapy is currently one of the most common/important treatments for cancers; however the occurrence of multidrug resistance (MDR) impedes the successful application of chemotherapeutic agents. The active efflux of anti-cancer drugs through multi-drug resistance protein 1 (MRP1) remains the dominant mechanism of MDR. However, mechanisms underlying the MRP1 upregulation during tumorigenesis and chemotherapy remain elusive. Methods: MRP1 expression, the efflux probability and viability were measured to evaluate MDR of human lung cancer A549/DDP and H1299 cells. Pharmacological treatment, shRNA-based konckdown and rescue were used to assess the function of JNK (c-Jun N-terminal kinase) and Sp1 (stimulatory phosphatase 1). Chromatin immunoprecipitation and dual-luciferase reporter assay were used to test the direct binding and activation of MRP1 promotor by Sp1. Findings: Pharmacological analysis and JNK knockdown revealed the direct modulation of MRP1 expression and MDR by by the JNK signaling pathway. Furthermore, the transcript factor Sp1 downstream of JNK showed close association with MRP1 expression and MDR. Chromatin immunoprecipitation and luciferase assays revealed the direct binding and activation of MRP1 promoter by Sp1, while Sp1 knockdown decreased MRP1 expression and reversed MDR. Importantly, the MRP1 upregulation and MDR mediated by JNK activation were substantially abolished by Sp1 knockdown in both A549/DDP and H1299 cells. Interpretation: This work demonstrates that Sp1 is a critical transcription factor for MRP1 downstream of JNK and plays a key role in MRP1 upregulation and MDR during tumorigenesis and chemotherapy. Targeting Sp1 expression/activation sheds new light on the clinical chemotherapy treatments of cancers.Funding Statement: This work was supported by the National Natural Science Foundation of China (31400708 and 31670843), the Natural Science Foundation of Heilongjiang Province, China (C200624, C201241, and C201453), the Shaanxi Natural Science Funds for Distinguished Young Scholars of China (2019JC-07), the Key Research and Development Program of Shaanxi Province, China (2017SF-113), and the Fundamental Research Funds for the Central Universities (2017qngz10).Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: Not required.
Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)

S-M He,R Li,J R Kanwar,S-F Zhou,S.-M. He,R. Li,J. R. Kanwar,S.-F. Zhou

DOI: https://doi.org/10.2174/092986711794839197

IF: 4.74

2011-01-01

Current Medicinal Chemistry

Abstract:Multidrug ABC transporters such as P-glycoprotein (P-gp/MDR1/ABCB1) and multidrug resistance protein 1 (MRP1/ABCC1) play an important role in the extrusion of drugs from the cell and their overexpression can be a cause of failure of anticancer and antimicrobial chemotherapy. Recently, the mouse P-gp/Abcb1a structure has been determined and this has significantly enhanced our understanding of the structure-activity relationship (SAR) of mammalian ABC transporters. This paper highlights our current knowledge on the structural and functional properties and the SAR of human MRP1/ABCC1. Although the crystal structure of MRP1/ABCC1 has yet to be resolved, the current topological model of MRP1/ABCC1 contains two transmembrane domains (TMD1 and TMD2) each followed by a nucleotide binding domain (NBD) plus a third NH2-terminal TMD0. MRP1/ABCC1 is expressed in the liver, kidney, intestine, brain and other tissues. MRP1/ABCC1 transports a structurally diverse array of important endogenous substances (e.g. leukotrienes and estrogen conjugates) and xenobiotics and their metabolites, including various conjugates, anticancer drugs, heavy metals, organic anions and lipids. Cells that highly express MRP1/ABCC1 confer resistance to a variety of natural product anticancer drugs such as vinca alkaloids (e.g. vincristine), anthracyclines (e.g. etoposide) and epipodophyllotoxins (e.g. doxorubicin and mitoxantrone). MRP1/ABCC1 is associated with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents. However, most compounds that efficiently reverse P-gp/ABCB1-mediated multidrug resistance have only low affinity for MRP1/ABCC1 and there are only a few effective and relatively specific MRP1/ABCC1 inhibitors available. A number of site-directed mutagenesis studies, biophysical and photolabeling studies, SAR and QSAR, molecular docking and homology modeling studies have documented the role of multiple residues in determining the substrate specificity and inhibitor selectivity of MRP1/ABCC1. Most of these residues are located in the TMs of TMD1 and TMD2, in particular TMs 4, 6, 7, 8, 10, 11, 14, 16, and 17, or in close proximity to the membrane/cytosol interface of MRP1/ABCC1. The exact transporting mechanism of MRP1/ABCC1 is unclear. MRP1/ABCC1 and other multidrug transporters are front-line mediators of drug resistance in cancers and represent important therapeutic targets in future chemotherapy. The crystal structure of human MRP1/ABCC1 is expected to be resolved in the near future and this will provide an insight into the SAR of MRP1/ABCC1 and allow for rational design of anticancer drugs and potent and selective MRP1/ABCC1 inhibitors.

pharmacology & pharmacy,biochemistry & molecular biology,chemistry, medicinal
Nodular posterior scleritis mimicking choroidal metastasis: a report of two cases

R. Hage,A. Jean-Charles,J. Guyomarch,O. Rahimian,A. Donnio,H. Merle

DOI: https://doi.org/10.2147/OPTH.S21255

2011-06-27

Clinical Ophthalmology

Abstract:Posterior scleritis is a rare underdiagnosed condition that can potentially cause blindness. Its varied presentations lead to delayed or incorrect treatment. We present here the cases of two patients with nodular posterior scleritis mimicking a choroidal metastasis. Two female patients presented with a sudden unilateral visual loss associated with ocular pain. Fundus examination revealed temporomacular choroidal masses with exudative detachments that, due to angiographic presentation, were suggestive of choroidal metastasis. Systemic examinations were unremarkable. In the two cases, a local or general anti-inflammatory treatment led to the complete recovery of the lesions, which were, thus, considered nodular posterior scleritis. The diagnosis of nodular posterior scleritis has to be evoked in all patients presenting with a choroidal mass in fundus examination. It represents the principal curable differential diagnosis of malignant choroidal tumor.
Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases

An-Kui Yang,Zhi-Wei Zhou,Min-Qian Wei,Jun-Ping Liu,Shu-Feng Zhou

DOI: https://doi.org/10.2174/156802610792928040

2010-12-01

Current Topics in Medicinal Chemistry

Abstract:Human multidrug resistance protein (MRP/ABCC) family contains 9 members (MRP1-9) which transport a structurally diverse array of anticancer and antimicrobial drugs and several important endogenous substances including prostaglandins (PGs) and leukotrienes (LTs) with different substrate specificity. MRP1-5 can collectively confer resistance to natural product anticancer drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, and alkylating agents. MRP1-3 are often associated with tumor resistance which is often caused by an increased efflux and decreased intracellular accumulation of natural product anticancer drugs and other anticancer agents. Both PGE(1) and PGE(2) are known high-affinity substrates of MRP4, but not MRP1, MRP2, MRP3 and MRP5. LTC(4) is a substrate of MRP1, MRP2, MRP3, and MRP6-8. MRP2 is also able to transport LTD(4) and LTE(4). Experimental studies in Abcc1-difficient mice have demonstrated a role of MRP1 in inflammation process in vivo. Abcc3-difficient mice have normal bile salt transport, however they have decreased blood bilirubin glucuronide levels. Abcc6-difficient mice show remarkable mineraliztion of the connective tissues, including skin, arterial blood vessels, and retina. Most MRP/ABCC transporters are subject to inhibition by a variety of compounds. Drug targeting of these transporters to overcome MRP/ABCC-mediated multidrug resistance may play a role in cancer and infection (e.g. HIV infection) chemotherapy. Some modulators of MRPs have shown reversing effects on MDR phenotype in preliminary clinical studies and some modulators of MRPs may modify the inflammatory process and consequently ameliorate the inflammatory symptoms. A better understanding of the interactions of these modulators with MRPs has important implications in development of novel drugs for treatment of cancer, infection and inflammation.

chemistry, medicinal
Transport of amphipathic anions by human multidrug resistance protein 3

H Zeng,G Liu,P A Rea,G D Kruh

2000-09-01

Abstract:The multidrug resistance-associated protein 1 (MRP1) and the canalicular multispecific organic anion transporter (cMOAT or MRP2) are ATP-binding cassette transporters that confer resistance to some anticancer drugs and efflux glutathione and glucuronate conjugates from the cell. The MRP subfamily of ABC transporters, however, contains at least four other members of which MRP3 (MOAT-D) bears the closest structural resemblance to MRP1. Although transfection studies have established that human MRP3 confers increased resistance to several anticancer agents, neither the substrate selectivity nor physiological functions of this transporter have been determined. Here we report the results of investigations of the in vitro transport properties of cloned human MRP3 using membrane vesicles prepared from MRP3-transfected HEK293 cells. It is shown that the expression of MRP3 is specifically associated with enhancement of the MgATP-dependent transport into membrane vesicles of the glucuronide estradiol 17-beta-D-glucuronide (E(2)17betaG), the glutathione conjugates 2,4-dinitrophenyl S-glutathione (DNP-SG) and leukotriene C4 (LTC4), the antimetabolite methotrexate, and the bile acid glycocholate. DNP-SG, LTC4, and E(2)17betaG are transported at moderate affinity and low capacity with Km and Vmax values of 5.7 +/- 1.7 microM and 3.8 +/- 0.1 pmol/mg/min, 5.3 +/- 2.6 microM and 20.2 +/- 5.9 pmol/mg/min, and 25.6 +/- 5.4 microM and 75.6 +/- 5.9 pmol/mg/min, respectively. Methotrexate and glycocholate are transported at low affinity and high capacity with Km and Vmax values of 776 +/- 319 microM and 288 +/- 54 pmol/mg/min and 248 +/- 113 microM and 183 +/- 34 pmol/mg/min, respectively. On the basis of these findings, the osmotic dependence of the transport measured and its inability to transport taurocholate, MRP3, like MRP1 and cMOAT, is concluded to be competent in the transport of glutathione S-conjugates, glucuronides, and methotrexate, albeit at low to moderate affinity. In contrast to MRP1, cMOAT, and all other characterized mammalian ABC transporters, however, MRP3 is active in the transport of the monoanionic human bile constituent glycocholate.
Multidrug Resistance-Associated Protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine Sulfoximine

Ilhan Akan,Selma Akan,Hakan Akca,Burhan Savas,Tomris Ozben

DOI: https://doi.org/10.1186/1475-2867-5-22

IF: 6.429

2005-07-24

Cancer Cell International

Abstract:Abstract Background Multidrug resistance mediated by the multidrug resistance-associated protein 1 (MRP1) decreases cellular drug accumulation. The exact mechanism of MRP1 involved multidrug resistance has not been clarified yet, though glutathione (GSH) is likely to have a role for the resistance to occur. N-acetylcysteine (NAC) is a pro-glutathione drug. DL-Buthionine (S,R)-sulfoximine (BSO) is an inhibitor of GSH synthesis. The aim of our study was to investigate the effect of NAC and BSO on MRP1-mediated vincristine resistance in Human Embryonic Kidney (HEK293) and its MRP1 transfected 293MRP cells. Human Embryonic Kidney (HEK293) cells were transfected with a plasmid encoding whole MRP1 gene. Both cells were incubated with vincristine in the presence or absence of NAC and/or BSO. The viability of both cells was determined under different incubation conditions. GSH, Glutathione S-Transferase (GST) and glutathione peroxidase (GPx) levels were measured in the cell extracts obtained from both cells incubated with different drugs. Results N-acetylcysteine increased the resistance of both cells against vincristine and BSO decreased NAC-enhanced MRP1-mediated vincristine resistance, indicating that induction of MRP1-mediated vincristine resistance depends on GSH. Vincristine decreased cellular GSH concentration and increased GPx activity. Glutathione S-Transferase activity was decreased by NAC. Conclusion Our results demonstrate that NAC and BSO have opposite effects in MRP1 mediated vincristine resistance and BSO seems a promising chemotherapy improving agent in MRP1 overexpressing tumor cells.

oncology
Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)

Caroline E Grant,Mian Gao,Marianne K DeGorter,Susan P C Cole,Roger G Deeley,Caroline E. Grant,Marianne K. DeGorter,Susan P. C. Cole,Roger G. Deeley

DOI: https://doi.org/10.1124/dmd.108.022491

2008-09-05

Drug Metabolism and Disposition

Abstract:Multidrug resistance proteins (MRPs) are members of the "C" branch of the ATP-binding cassette transporter superfamily. Human MRP1 transports a wide range of natural product drugs and structurally diverse conjugated and unconjugated organic anions. Its closest relative is MRP3. Despite their structural similarity, the homologs differ substantially in their substrate specificity. It is noteworthy that MRP1 transports glutathione (GSH) and GSH conjugates and displays GSH-stimulated transport of a number of unconjugated and conjugated compounds. In contrast, MRP3 does not transport GSH and is a poor transporter of GSH conjugates. However, both proteins transport glucuronide conjugates, such as 17beta-estradiol 17-(beta-D-glucuronide). We have constructed a series of MRP1/MRP3 hybrids and used them to identify a region of MRP1 that is critical for binding and transport of GSH conjugates such as leukotriene C(4) (LTC(4)). Substitution of this region encompassing transmembrane helices 8 and 9 and portions of cytoplasmic loops 4 and 5 of MRP1 with the equivalent region of MRP3 eliminated LTC(4) transport. Transport of other substrates was either unaffected or enhanced. We identified three residues in this region: Tyr(440), Ile(441), and Met(443), mutation of which differentially affected transport. It is noteworthy that substitution of Tyr(440) with Phe, as found in MRP3, reduced LTC(4) and GSH-stimulated estrone-3-sulfate transport without affecting transport of other substrates tested. The mutation increased the K(m) for LTC(4) 5-fold and substantially reduced photolabeling of MRP1 by both [3H]LTC(4) and the GSH derivative, azidophenacyl-[35S]GSH. These results suggest that Tyr(440) makes a major contribution to recognition of GSH and the GSH moiety of conjugates such as LTC(4).

pharmacology & pharmacy
[Effect of Arsenic Trioxide on Drug Transporting Molecules in Acute Promyelocytic Leukemia Cell Line].

Xiao-ping Qian,Bao-rui Liu,Hai-tao Yin,Li-feng Wang,Zheng-yun Zou,Juan Du

DOI: https://doi.org/10.3760/j.issn:0253-3766.2004.10.007

2004-01-01

Abstract:OBJECTIVE:To study the effect of arsenic trioxide (As2O3) on expression of drug transporting molecules in APL MR2 cell line.METHODS:MR2 resistant to all-trans retinoic acid (ATRA) and non-ATRA resistant APL cell line NB4 was used in this in vitro study. Expression of P-glycoprotein (Pgp), multidrug resistance protein (MRP) and lung resistance-related protein (LRP) was detected by immunocytochemical assay.RESULTS:The expression of Pgp was significantly higher in MR2 (30%-40%) than in NB4 (10%-20%) (P < 0.001), and that of MRP was also higher in MR2 (56.9 +/- 3.4-21.2 +/- 1.1) than in NB4 (20.6 +/- 5.3-16.7 +/- 1.2) (P < 0.001). As2O3 at concentrations ranging from 0.5 approximately 2.0 micromol/L could significantly decrease the expression of Pgp and MRP, but not that of LRP. The decrease in the expression of Pgp and MRP in MR2 cell line was negatively correlated with the dose and duration of action of As2O3.CONCLUSION:Pgp and MRP, but not LRP, may be the sensitive targets of As2O3 to overcome drug-resistance. ATRA might be the substrates of Pgp and MRP.
Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation

Adrian C Jaramillo,Jacqueline Cloos,Clara Lemos,Ronald W Stam,Gertjan J L Kaspers,Gerrit Jansen,Godefridus J Peters

DOI: https://doi.org/10.1016/j.leukres.2019.02.008

Abstract:Chemoresistance is an important factor in the treatment failure of childhood acute lymphoblastic leukemia (ALL). One underlying mechanism of chemoresistance involves (over)expression of ATP-dependent drug efflux transporters such as multidrug resistance protein 1-5 (MRP1-5) and breast cancer resistance protein (BCRP), which can extrude the important antileukemia drug methotrexate (MTX). Survival of childhood ALL critically depends on the leukemic blasts' capacity for intracellular retention of MTX and MTX-polyglutamates. This pilot study assessed whether expression of MRP1, MRP4, MRP5 and BCRP (real-time PCR) in primary childhood ALL blasts (n = 23) correlated with ex vivo resistance to MTX (assayed by in situ thymidylate synthase inhibition assay (TSIA)), ex vivo accumulation of (radioactive) MTX polyglutamates, and patient survival. Results show that high MRP4 expression is correlated with ex vivo MTX resistance assayed by TSIA (P = 0.01). Moreover, elevated MRP4 and BCRP expression correlated with lower accumulation of MTX-PGs (P = 0.004 and P = 0.03, respectively). Combined high expression of BCRP and MRP4 even further impacted reduced MTX-PG accumulation (P = 0.02). Overall survival was lower (P logrank = 0.04) in children with ALL cells which featured a relatively high expression of both BCRP and MRP4 transporters. These results underscore the impact of high drug efflux transporter expression, notably MRP4 and BCRP, in diminished MTX response in childhood ALL.
Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells

Kee W. Tan,Angelina Sampson,Bremansu Osa-Andrews,Surtaj H. Iram

DOI: https://doi.org/10.1124/dmd.118.081612

2018-09-19

Drug Metabolism and Disposition

Abstract:Efflux transporters P-glycoprotein (P-gp/ABCB1), multidrug resistance protein 1 (MRP1/ABCC1), and breast cancer resistance protein (BCRP/ABCG2) can affect the efficacy and toxicity of a wide variety of drugs and are implicated in multidrug resistance (MDR). Eight test compounds, recently identified from an intramolecular FRET-based high throughput screening, were characterized for their interaction with MRP1. We report that the active metabolite of vitamin D3, calcitriol, and its analog calcipotriol are selectively cytotoxic to MRP1-overexpressing cells, besides inhibiting transport function of P-gp, MRP1, and BCRP. Calcitriol and calcipotriol consistently displayed a potent inhibitory activity on MRP1-mediated doxorubicin and calcein efflux in MRP1-overexpressing H69AR and HEK293/MRP1 cells. Vesicular transport studies confirmed a strong inhibitory effect of calcitriol and calcipotriol on MRP1-mediated uptake of tritium-labeled estradiol glucuronide and leukotriene C4 In cytotoxicity assays, MRP1-overexpressing cells exhibited hypersensitivity toward calcitriol and calcipotriol. Such collateral sensitivity, however, was not observed in HEK293/P-gp and HEK293/BCRP cells, although the vitamin D3 analogs inhibited calcein efflux in P-gp-overexpressing cells, and mitoxantrone efflux in BCRP-overexpressing cells. The selective cytotoxicity of calcitriol and calpotriol toward MRP1 over-expressing cells can be eliminated with MRP1 inhibitor MK571. Our data indicate a potential role of calcitriol and its analogs in targeting malignancies in which MRP1 expression is prominent and contributes to MDR.

pharmacology & pharmacy
Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite

Reem Ali,Abdallah Alhaj Sulaiman,Bushra Memon,Singdhendubala Pradhan,Mashael Algethami,Mustapha Aouida,Gordon McKay,Srinivasan Madhusudan,Essam M. Abdelalim,Dindial Ramotar

DOI: https://doi.org/10.3390/cells12232682

IF: 6

2023-11-23

Cells

Abstract:Targeting tumour metabolism through glucose transporters is an attractive approach. However, the role these transporters play through interaction with other signalling proteins is not yet defined. The glucose transporter SLC2A3 (GLUT3) is a member of the solute carrier transporter proteins. GLUT3 has a high affinity for D-glucose and regulates glucose uptake in the neurons, as well as other tissues. Herein, we show that GLUT3 is involved in the uptake of arsenite, and its level is regulated by peroxiredoxin 1 (PRDX1). In the absence of PRDX1, GLUT3 mRNA and protein expression levels are low, but they are increased upon arsenite treatment, correlating with an increased uptake of glucose. The downregulation of GLUT3 by siRNA or deletion of the gene by CRISPR cas-9 confers resistance to arsenite. Additionally, the overexpression of GLUT3 sensitises the cells to arsenite. We further show that GLUT3 interacts with PRDX1, and it forms nuclear foci, which are redistributed upon arsenite exposure, as revealed by immunofluorescence analysis. We propose that GLUT3 plays a role in mediating the uptake of arsenite into cells, and its homeostatic and redox states are tightly regulated by PRDX1. As such, GLUT3 and PRDX1 are likely to be novel targets for arsenite-based cancer therapy.

cell biology
Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28)

U Giri,N H A Terry,S V Kala,M W Lieberman,M D Story

DOI: https://doi.org/10.1007/s00280-004-0920-0

Abstract:Purpose: Arsenic, in the form of As(2)O(3), has gained therapeutic importance because it has been shown to be very effective clinically in the treatment of acute promyelocytic leukemia (APL). Via numerous pathways arsenic induces cellular alterations such as induction of apoptosis, inhibition of cellular proliferation, stimulation of differentiation, and inhibition of angiogenesis. Responses vary depending on cell type, dose and the form of arsenic. GSTO1, a member of the glutathione S-transferase superfamily omega, has recently been shown to be identical to the rate-limiting enzyme, monomethyl arsenous (MMA(V)) reductase which catalyzes methylarsonate (MMA(V)) to methylarsenous acid (MMA(III)) during arsenic biotransformation. In this study, we investigated whether arsenic trioxide (As(2)O(3)) induces apoptosis in both chemosensitive and chemoresistant cell lines that varied in their expression of p28 (gsto1), the mouse homolog of GSTO1. Methods: The cytotoxicity of arsenic in the gsto1- and bcl-2-expressing chemoresistant and radioresistant LY-ar mouse lymphoma cell line, was compared with that of the LY-ar's parental cell line, LY-as. LY-as cells are radiosensitive, apoptotically permissive, and do not express gsto1 or bcl-2. Cell survival, glutathione (GSH) levels, mitochondrial membrane potential, and stress-activated kinase status after arsenic treatment were examined in these cell lines. Results: As(2)O(3) induced an equivalent dose- and time-dependent increase in apoptosis in these cell lines. Cellular survival, as measured after a 24-h exposure, was also the same in each cell line. Reduced GSH was modulated in a similar time- and dose-dependent manner. Apoptosis was preceded by loss of mitochondrial membrane potential that triggered caspase-mediated pathways associated with apoptosis. With a prolonged exposure of As(2)O(3), both cell lines showed decreased activation of ERK family members, ERK1, ERK2 and ERK5. As(2)O(3) enhanced the death signals in LY-ar cells through a decrease in GSH, loss of mitochondrial membrane potential, and abatement of survival signals. This effect is similar to that seen when LY-ar cells are treated with thiol-depleting agents or by the removal of methionine and cysteine (GSH precursor) from the growth medium. This response is also completely contrary to that seen for radiation, actinomycin D, VP-16 and other agents, where LY-ar cells do not succumb to apoptosis. Conclusions: The overexpression of gsto1 in normally chemoresistant and radioresistant LY-ar cells renders them vulnerable to the cytotoxic effects of As(2)O(3), despite the 30-fold overexpression of the survival factor bcl-2. Gsto1 and its human homolog, GSTO1, may serve as a marker for arsenic sensitivity, particularly in cells that are resistant to other chemotherapeutic agents.
Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.

Jian Cheng,Weiwei Wu,Bao-an Chen,Feng Gao,Wenlin Xu,Chong Gao,Jiahua Ding,Yunyu Sun,Huihui Song,Wen Bao,Xinchen Sun,Cuirong Xu,Wenji Chen,Ningna Chen,Lijie Liu,Guohua Xia,Xiaomao Li,Xuemei Wang

DOI: https://doi.org/10.2147/ijn.s7090

IF: 7.033

2009-01-01

International Journal of Nanomedicine

Abstract:This study aims to evaluate the multidrug resistance (MDR) reversal activity by magnetic nanoparticles of Fe3O4 (MNPs-Fe3O4) and 5-bromotetrandrine (BrTet) MDR cell line K562/A02 solitarily or symphysially. The proliferation of K562 and K562/A02 cells and the cytotoxicity on peripheral blood mononuclear cells (PMBCs) were evaluated by MTT assay. Cellular accumulation of daunorubicin (DNR) was analyzed by flow cytometry. Real-time polymerase chain reaction and Western blotting analyses were performed to examine the mRNA and protein levels of mdr1, respectively. The results showed that the combination of MNPs-Fe3O4 and BrTet with effective concentrations significantly increased cytotoxicity against MDR cell line K562/A02. Both BrTet and MNPs-Fe3O4 increased the intracellular DNR accumulation in the K562/A02 cell line, and downregulated the level of mdr1 gene and expression of P-glycoprotein. Furthermore, the combination did not have significant cytotoxicity in PMBCs. We propose that MNPs-Fe3O4 conjugated with DNR and BrTet probably have synergetic effects on MDR reversal.
The Overexpression of Multidrug Resistance-Associated Proteins and Gankyrin Contribute to Arsenic Trioxide Resistance in Liver and Gastric Cancer Cells

Xi Chen,Mu Zhang,Lian-Xin Liu

DOI: https://doi.org/10.3892/or_00000408

2009-01-01

Oncology Reports

Abstract:Arsenic trioxide has been used as a therapeutic agent for acute promyelocytic leukemia and recently for some solid tumors. Although arsenic trioxide has been shown to significantly inhibit the growth of solid tumor cells in vitro, clinical trials indicate that arsenic trioxide alone is pool active against non-hematologic malignant diseases. To understand the mechanisms of arsenic resistance in solid tumor cells, we established two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, isolated from human liver cancer cell line HepG2 and human gastric cancer cell line SGC7901, respectively, by a series of stepwise selections via treatment with increasing concentrations of arsenic trioxide. Three ABC transporter proteins, ABCB1, ABCC1 and ABCC2, were expressed increasingly and differently in two arsenic-resistant cell lines. Further, tumor suppressor p53 was overexpressed in two arsenic-resistant cell lines, but the levels of p53 mediators MDM2 and gankyrin, which regulate the ubiquitination of p53, increased simultaneously. In addition, an increase in the phosphorylation of Rb at Ser795 in the two cell lines might also result from the presence of MDM2 and gankyrin, which suggest that the inactivation of p53 and Rb contribute to drug resistance. These two arsenic-resistant solid tumor cell lines, HepG2/AS and SGC7901/AS, may be useful for studying the mechanism of arsenic resistance in solid tumors and may provide a way to overcome it.
Biliary excretion of arsenic by human HepaRG cells is stimulated by selenide and mediated by the multidrug resistance protein 2 (MRP2/ABCC2)

Janet R Zhou,Gurnit Kaur,Yingze Ma,Denis Arutyunov,Xiufen Lu,X Chris Le,Elaine M Leslie

DOI: https://doi.org/10.1016/j.bcp.2021.114799

Abstract:Millions of people worldwide are exposed to unacceptable levels of arsenic, a proven human carcinogen, in drinking water. In animal models, arsenic and selenium are mutually protective through formation and biliary excretion of seleno-bis (S-glutathionyl) arsinium ion [(GS)2AsSe]-. Selenium-deficient humans living in arsenic-endemic regions are at increased risk of arsenic-induced diseases, and may benefit from selenium supplementation. The influence of selenium on human arsenic hepatobiliary transport has not been studied using optimal human models. HepaRG cells, a surrogate for primary human hepatocytes, were used to investigate selenium (selenite, selenide, selenomethionine, and methylselenocysteine) effects on arsenic hepatobiliary transport. Arsenite + selenite and arsenite + selenide at different molar ratios revealed mutual toxicity antagonism, with the latter being higher. Significant levels of arsenic biliary excretion were detected with a biliary excretion index (BEI) of 14 ± 8%, which was stimulated to 32 ± 7% by selenide. Consistent with the formation and biliary efflux of [(GS)2AsSe]-, arsenite increased the BEI of selenide from 0% to 24 ± 5%. Arsenic biliary excretion was lost in the presence of selenite, selenomethionine, and methylselenocysteine. Sinusoidal export of arsenic was stimulated ∼1.6-fold by methylselenocysteine, but unchanged by other selenium forms. Arsenic canalicular and sinusoidal transport (±selenide) was temperature- and GSH-dependent and inhibited by MK571. Knockdown experiments revealed that multidrug resistance protein 2 (MRP2/ABCC2) accounted for all detectable biliary efflux of arsenic (±selenide). Overall, the chemical form of selenium and human MRP2 strongly influenced arsenic hepatobiliary transport, information critical for human selenium supplementation in arsenic-endemic regions.

CEUDEX: a data base oriented to context-dependent units training in Spanish for continuous speech recognition

Disruption of mitochondrial redox homeostasis as a mechanism of antimony-induced reactive oxygen species and cytotoxicity

Monomethylarsenic Diglutathione Transport By The Human Multidrug Resistance Protein 1 (Mrp1/Abcc1)

Differential Specificity of the Human and Mouse Multidrug Resistance Protein 4 (MRP4) Orthologs for Arsenic Metabolites

Multidrug Resistance Protein 1 ( ABCC1 ) Confers Resistance to Arsenic Compounds in Human Myeloid Leukemic HL-60 Cells

Precursors of Engine Failures Revealed by Wavelet Analysis

SP1 Mediates MRP1 Upregulation and Multi-Drug Resistance in Human Lung Cancer Cells

Structural and Functional Properties of Human Multidrug Resistance Protein 1 (MRP1/ABCC1)

Nodular posterior scleritis mimicking choroidal metastasis: a report of two cases

Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases

Transport of amphipathic anions by human multidrug resistance protein 3

Multidrug Resistance-Associated Protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine Sulfoximine

Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3)

[Effect of Arsenic Trioxide on Drug Transporting Molecules in Acute Promyelocytic Leukemia Cell Line].

Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation

Calcitriol and Calcipotriol Modulate Transport Activity of ABC Transporters and Exhibit Selective Cytotoxicity in MRP1-overexpressing Cells

Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite

Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28)

Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.

The Overexpression of Multidrug Resistance-Associated Proteins and Gankyrin Contribute to Arsenic Trioxide Resistance in Liver and Gastric Cancer Cells

Biliary excretion of arsenic by human HepaRG cells is stimulated by selenide and mediated by the multidrug resistance protein 2 (MRP2/ABCC2)